ATE319460T1 - Onkolytisches vesicular stomatitis virus - Google Patents

Onkolytisches vesicular stomatitis virus

Info

Publication number
ATE319460T1
ATE319460T1 AT00965106T AT00965106T ATE319460T1 AT E319460 T1 ATE319460 T1 AT E319460T1 AT 00965106 T AT00965106 T AT 00965106T AT 00965106 T AT00965106 T AT 00965106T AT E319460 T1 ATE319460 T1 AT E319460T1
Authority
AT
Austria
Prior art keywords
virus
vesicular stomatitis
tumor cell
pkr
stomatitis virus
Prior art date
Application number
AT00965106T
Other languages
German (de)
English (en)
Inventor
John Cameron Bell
Nahum Sonenberg
David Francis Stojdl
Earl Garnet Brown
Harold Lawrence Atkins
Ricardo Marcellus Marius
Brian Dennis Lichty
Shane Brendan Knowles
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of ATE319460T1 publication Critical patent/ATE319460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT00965106T 1999-09-17 2000-09-18 Onkolytisches vesicular stomatitis virus ATE319460T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17

Publications (1)

Publication Number Publication Date
ATE319460T1 true ATE319460T1 (de) 2006-03-15

Family

ID=23573018

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00965106T ATE319460T1 (de) 1999-09-17 2000-09-18 Onkolytisches vesicular stomatitis virus
AT05025974T ATE418341T1 (de) 1999-09-17 2000-09-18 Onkolytisches virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05025974T ATE418341T1 (de) 1999-09-17 2000-09-18 Onkolytisches virus

Country Status (13)

Country Link
EP (2) EP1716858B9 (cg-RX-API-DMAC7.html)
JP (1) JP5060694B2 (cg-RX-API-DMAC7.html)
CN (1) CN1289098C (cg-RX-API-DMAC7.html)
AT (2) ATE319460T1 (cg-RX-API-DMAC7.html)
AU (1) AU782402B2 (cg-RX-API-DMAC7.html)
CA (1) CA2386920C (cg-RX-API-DMAC7.html)
DE (2) DE60026554T2 (cg-RX-API-DMAC7.html)
ES (2) ES2260057T3 (cg-RX-API-DMAC7.html)
HK (1) HK1044708B (cg-RX-API-DMAC7.html)
IL (2) IL148621A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02002772A (cg-RX-API-DMAC7.html)
NZ (4) NZ523805A (cg-RX-API-DMAC7.html)
WO (1) WO2001019380A2 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
WO2002000233A2 (en) 2000-06-26 2002-01-03 Wellstat Biologics Corporation Purging of cells using viruses
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
CA2452517A1 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Hsvを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
ATE539162T1 (de) 2003-03-27 2012-01-15 Ottawa Hospital Res Inst Mutierte viren der vesikulären stomatitis und deren verwendung
CA2568772A1 (en) 2004-06-01 2005-12-15 San Diego State University Foundation Expression system based on recombinant vesicular stomatitis virus synthesizing t7 rna polymerase
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
ZA200702269B (en) * 2004-08-20 2008-09-25 Viralytics Ltd Methods and compositions for treatment of hematologic cancers
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2009082664A2 (en) * 2007-12-21 2009-07-02 Wyeth Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
US10603351B2 (en) 2008-08-21 2020-03-31 Turnstone Limited Partnership Engineered synergistic oncolytic viral symbiosis
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
WO2010105347A1 (en) 2009-03-16 2010-09-23 Mcmaster University Vaccination methods
WO2011070440A2 (en) 2009-12-10 2011-06-16 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
JP5944901B2 (ja) * 2010-09-02 2016-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 水疱性口内炎ウイルス
EP2718427B1 (en) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions for glioblastoma treatment
WO2013050048A2 (en) 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
RU2019107976A (ru) 2013-02-21 2019-08-23 Тёрнстоун Лимитед Партнершип Композиция вакцины
EP3906931A3 (en) * 2013-04-10 2022-02-23 iSD Immunotech ApS Use of immune suppressive domains as medicaments
US10066214B2 (en) 2013-06-14 2018-09-04 Turnstone Limited Partnership Compositions and methods for enhancing virus replication
EP2826856B9 (en) * 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
US11015229B2 (en) 2014-07-21 2021-05-25 Novellusdx Ltd. Methods and systems for determining oncogenic index of patient specific mutations
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
US12351812B2 (en) 2017-05-19 2025-07-08 Georgia State University Research Foundation, Inc. Recombinant oncolytic virus
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
PT3684786T (pt) 2017-09-22 2024-10-30 Centre Nat Rech Scient Glicoproteína mutante do vírus da estomatite vesicular
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
US20240318147A1 (en) * 2020-08-14 2024-09-26 Revoimmune Therapeutics Inc. Recombinant oncolytic virus, and construction method therefor and use thereof
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CA3212006A1 (en) 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
EP4784626A1 (en) 2023-09-25 2026-08-05 Kelonia Therapeutics, Inc. Antigen binding polypeptides
IL327310A (en) 2023-09-25 2026-05-01 Kelonia Therapeutics Inc Cancer treatment vehicles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
ES2188593T3 (es) * 1992-03-24 2003-07-01 United Cancer Res Inst Vacuna que contiene un virus vivo.
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
EP1314430A1 (en) 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Treatment of non-neuronal cancer using HSV mutant
DE69837764T2 (de) * 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
EP1905304A3 (en) * 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
IL136905A0 (en) * 1997-12-22 2001-06-14 Univ Tennessee Res Corp Recombinant rhabdovirus containing a heterologous fusion protein
EP1061806A4 (en) * 1998-03-12 2001-09-12 Univ Pennsylvania PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
SK288544B6 (sk) * 1998-06-12 2018-03-05 Mount Sinai School Of Medicine Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤

Also Published As

Publication number Publication date
IL148621A0 (en) 2002-09-12
EP1218019B1 (en) 2006-03-08
CN1289098C (zh) 2006-12-13
ES2260057T3 (es) 2006-11-01
AU782402B2 (en) 2005-07-28
MXPA02002772A (es) 2004-04-02
DE60041210D1 (de) 2009-02-05
NZ534307A (en) 2005-07-29
NZ534306A (en) 2005-12-23
EP1218019A2 (en) 2002-07-03
AU7588200A (en) 2001-04-17
JP2004525855A (ja) 2004-08-26
ES2320239T3 (es) 2009-05-20
CA2386920A1 (en) 2001-03-22
WO2001019380A3 (en) 2001-11-22
HK1044708B (en) 2006-10-27
JP5060694B2 (ja) 2012-10-31
DE60026554D1 (de) 2006-05-04
HK1044708A1 (en) 2002-11-01
NZ523805A (en) 2004-09-24
NZ517573A (en) 2004-02-27
EP1716858A2 (en) 2006-11-02
EP1716858B1 (en) 2008-12-24
CA2386920C (en) 2012-01-24
IL148621A (en) 2010-02-17
WO2001019380A2 (en) 2001-03-22
CN1496268A (zh) 2004-05-12
EP1716858B9 (en) 2009-08-12
ATE418341T1 (de) 2009-01-15
EP1716858A3 (en) 2007-08-15
DE60026554T2 (de) 2006-09-28
HK1092713A1 (en) 2007-02-16

Similar Documents

Publication Publication Date Title
DE60026554D1 (de) Onkolytisches vesicular stomatitis virus
DE60239394D1 (de) Onkolytische virustherapie
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
MY133891A (en) Polyethylene glycol modified interferon therapy
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
DE69528751D1 (de) Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
ATE412666T1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
DE69902103D1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
EP0592685A4 (en) PLANT RESISTANT TO AT LEAST TWO VIRUSES AND THEIR PREPARATION.
ATE155795T1 (de) Verwendung von leukoregulin zur behandlung von mit einem envelope-virus infizierten tier
WO2003015714A3 (en) Compositions and therapeutic methods for viral infection
SG165996A1 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
Warfel et al. Production and initial characterization of guinea pig interferon
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE26267T1 (de) Pyrimidin-derivate, ausgestattet mit antiviraler wirkung.
Eylan et al. Resistance of aged cells to virus replication
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
RU98109203A (ru) Способ лечения вирусного гепатита b у детей
DK0979093T3 (da) Terapeutisk virusmiddel, hvis udvikling kan standses
DE69422980D1 (de) Extrakte von Piliostigma thonningii, deren Verwendung und diese enthaltende Zubereitungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218019

Country of ref document: EP